In this issue:
Timing of high-efficacy therapy for MS
Postero-anterior gradient of CC damage in MS
Impact of physical exercise on fatigue in MS
IVIG for the prevention of postpartum relapses in MS
Risk factors for reactivation of clinical disease activity in MS after natalizumab cessation
High-dose vitamin D supplementation in MS
Risk of serious infections associated with DMTs for MS.
Increased serological response against HHV-6A is associated with risk for MS
End of dose interval symptoms in patients treated with natalizumab
Fingolimod and dimethyl-fumaratederived lymphopaenia is not associated with short-term treatment
response and risk of infections
Please login below to download this issue (PDF)